Deborah Hartman, PhD

Chief Scientific Officer

Orexia Therapeutics

Deborah Hartman, PhD, is Chief Scientific Officer at Orexia Therapeutics. Deborah has over twenty years of experience in drug discovery and development and has held multiple leadership roles in the pharmaceutical industry. Most recently, Deborah was the Global Program Leader at Takeda Pharmaceutical Company, Ltd., where she led the development of a multi-asset Orexin Receptor 2 (OX2R) agonist clinical stage franchise. This program provided the first clinical evidence that demonstrated proof of concept for OX2R agonists in enhancing wakefulness across multiple indications including Narcolepsy Type 1 and Type 2, as well as in healthy adults.

Deborah held earlier roles at AstraZeneca, PLC, as Vice President of Respiratory and Inflammation Research in Charnwood, UK; Vice President of Projects in the Innovative Medicines Unit (iMed) for Infectious Diseases in Cambridge, Massachusetts, USA; and Vice President of Global Lead Generation Enabling Sciences in Alderley Park, UK, with additional responsibility for sites in Boston, Massachusetts, USA and in Sweden. Deborah started her career in drug discovery at F. Hoffmann-La Roche, AG, in Basel, Switzerland, where she was a Project Leader in the Neuroscience area and later in the Metabolic Diseases group based in New Jersey, USA.

In addition to her experience in major pharmaceutical companies, Deborah also held the position of Vice President of Research at Avaxia Biologics, Inc., a clinical stage biotechnology company in the Boston area which developed a novel platform for orally administered antibody therapeutics.

Deborah received her Bachelor’s Degree in Molecular Biology at Princeton University and holds a PhD in Molecular and Cellular Biology from Yale University.

Read more here about Orexia Therapeutics

Your browser is out-of-date!

Update your browser to view this website correctly. Outdated Browser